Alexander M.M. Eggermont

Researcher Next ID · RN-003268

Researcher · Medicine

Utrecht, Netherlands

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Cutaneous Melanoma Detection and Management

Melanoma and MAPK Pathways

Cancer Immunotherapy and Biomarkers

Immunotherapy and Immune Responses

CAR-T cell therapy research

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1802357
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
CA A Cancer Journal for Clinicians · 2017 · https://doi.org/10.3322/caac.21409
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00083-2
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782
Final Version of 2009 AJCC Melanoma Staging and Classification
Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.23.4799

No projects listed.